Stocks and Investing Stocks and Investing
Tue, July 9, 2024

Matthew Sykes Maintained (TXG) at Strong Sell with Decreased Target to $16 on, Jul 9th, 2024


Published on 2024-10-28 12:17:51 - WOPRAI, Matthew Sykes
  Print publication without navigation


Matthew Sykes of Goldman Sachs, Maintained "10x Genomics, Inc." (TXG) at Strong Sell with Decreased Target from $26 to $16 on, Jul 9th, 2024.

Matthew has made no other calls on TXG in the last 4 months.



There are 10 other peers that have a rating on TXG. Out of the 10 peers that are also analyzing TXG, 6 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Doug Schenkel of "Wolfe Research" Downgraded from Buy to Hold on, Thursday, June 27th, 2024
  • Subbu Nambi of "Guggenheim" Downgraded from Strong Buy to Hold on, Wednesday, June 26th, 2024
  • Tycho Peterson of "Jefferies" Initiated at Hold and Held Target at $24 on, Monday, June 3rd, 2024
  • Dan Brennan of "TD Cowen" Downgraded from Strong Buy to Hold and Decreased Target to $32 on, Wednesday, May 1st, 2024
  • Dan Leonard of "UBS" Maintained at Hold with Decreased Target to $30 on, Wednesday, May 1st, 2024
  • Derik De Bruin of "B of A Securities" Maintained at Hold with Decreased Target to $36 on, Wednesday, May 1st, 2024


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Luke Sergott of "Barclays" Maintained at Buy with Decreased Target to $24 on, Friday, June 28th, 2024
  • Daniel Arias of "Stifel" Maintained at Strong Buy with Decreased Target to $53 on, Wednesday, May 1st, 2024
  • Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $50 on, Monday, April 29th, 2024
  • Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $55 on, Thursday, April 18th, 2024
Contributing Sources